Erythema Migrans

What is it?

Erythema migrans represents the characteristic skin manifestation of early Lyme disease, appearing as an expanding red rash at the site of an infected tick bite. This distinctive eruption develops when Borrelia burgdorferi bacteria (the causative agent of Lyme disease) spread through the skin following transmission from an infected Ixodes tick (deer tick or black-legged tick). The rash typically emerges 7-14 days after the tick bite, though it may appear anywhere from 1 to 28 days post-exposure. Erythema migrans serves as the most recognizable and pathognomonic (uniquely characteristic) sign of Lyme disease, occurring in approximately 70-80% of infected individuals. The presence of this rash allows for immediate clinical diagnosis and treatment initiation without requiring laboratory confirmation.

Who is affected?

Erythema migrans affects individuals exposed to infected ticks in endemic areas:

• Geographic distribution: Highest incidence in northeastern and upper midwestern United States; also prevalent in Europe with different bacterial species
• Annual occurrence: Over 89,000 Lyme disease cases reported in the US (2023), with estimated 476,000 people diagnosed and treated annually
• Age patterns: Affects all ages; children with multiple rashes tend to be younger (mean 4.5 years) than those with single lesions (mean 6.5 years)
• Seasonal variation: Peak incidence during late spring and early summer when nymphal ticks are most active
• Risk factors: Outdoor activities in wooded or grassy areas, gardening, hiking, camping in endemic regions
• Occupation risks: Forestry workers, landscapers, park rangers, outdoor recreation professionals
• Regional incidence: Norway reports 148 cases per 100,000 inhabitants annually; some high-incidence areas reach 448 per 100,000

What causes it?

The rash results from complex interactions between infecting bacteria and host immune response:

Causative organisms:

• United States: Borrelia burgdorferi sensu stricto (exclusively)
• Europe: B. afzelii (most common), B. garinii, B. bavariensis, B. spielmanii
• Vector transmission: Ixodes scapularis (eastern US), I. pacificus (western US), I. ricinus (Europe)
• Transmission time: Typically requires 24-48 hours of tick attachment; occasionally faster

Pathogenesis:

• Initial infection: Bacteria enter skin during tick feeding, multiply locally
• Local spread: Organisms migrate outward through skin, creating expanding rash
• Immune response: Inflammatory reaction produces visible erythema (redness)
• Dissemination: Without treatment, bacteria spread via blood and lymphatics to distant sites

What are the clinical features?

Erythema migrans presents with characteristic features that vary geographically:

Classic appearance:

• Expanding lesion: Starts as small red spot, gradually expands outward (can reach 20 cm diameter)
• "Bull's-eye" pattern: Central clearing with concentric rings—but only 20% of US cases show this classic pattern
• European presentation: 80% exhibit bull's-eye appearance due to different Borrelia species
• US presentation: Most appear as uniform red or bluish patches without central clearing
• Texture: Warm to touch, generally flat, may be slightly raised at edges
• Sensation: Usually painless; may burn or itch mildly

Associated symptoms:

• Systemic features: Fever, chills, headache, fatigue, muscle aches (myalgia), joint pain (arthralgia)
• Lymph node enlargement: Regional lymphadenopathy (swollen lymph nodes near the rash)
• Multiple lesions: 20% develop secondary erythema migrans lesions from blood-borne spread
• Timing: Most patients don't recall the preceding tick bite due to tiny nymph size (2mm)

How is it diagnosed?

Diagnosis relies primarily on clinical recognition in endemic areas:

Diagnosis:

• Clinical diagnosis preferred: Characteristic rash in patient with potential tick exposure
• Laboratory testing: Not recommended for typical erythema migrans; low sensitivity in early disease
• Blood tests: Often negative when rash first appears; antibodies develop later
• Differential diagnosis: Must distinguish from spider bites, ringworm, cellulitis, contact dermatitis

Treatment (first-line antibiotics):

• Doxycycline: 100 mg twice daily for 10 days (preferred; also covers other tick-borne infections)
• Amoxicillin: 500 mg three times daily for 14 days (alternative for those unable to take doxycycline)
• Cefuroxime axetil: 500 mg twice daily for 14 days (beta-lactam alternative)
• Azithromycin: 500 mg daily for 5-10 days (less effective; more treatment failures)

Treatment response:

• Success rate: >90% complete recovery with prompt appropriate antibiotics
• Resolution time: Rash fades within days to weeks of starting treatment
• Prevention benefit: Early treatment prevents progression to disseminated Lyme disease

What is the prognosis?

With timely treatment, outcomes are excellent:

• Early treatment: >90% return to previous health status completely
• Rapid recovery: Most patients recover quickly with appropriate antibiotics
• Complication prevention: Prompt treatment prevents late Lyme disease manifestations (arthritis, neurological, cardiac)
• Untreated progression: 60% of untreated cases develop disseminated disease (joint, heart, nervous system involvement)
• Post-treatment syndrome: Approximately 10% experience lingering fatigue and pain despite successful treatment
• Recurrence prevention: Single-dose doxycycline prophylaxis effective if given within 72 hours of high-risk tick removal